

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司

CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE

The board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that the Company has decided to implement a share repurchase program (the “**Share Repurchase Program**”) through the exercise of the general mandate to repurchase shares of the Company (the “**Shares**”) that has been granted by the shareholders of the Company (the “**Shareholders**”) to the Board at the annual general meeting held on 26 May 2026 (the “**Repurchase Mandate**”). The Company will repurchase the Shares from the open market.

Details of the Share Repurchase Program are as follows:

Aggregate amount of capital available for the : Up to HKD200 million
proposed Share repurchase

Period for the proposed Share repurchase : From 27 May 2026 to 31 December 2026

Under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the repurchase price of each Share shall not be more than 5% higher than the average closing market price for the Shares over the 5 trading days immediately preceding each repurchase.

The Board is confident in the business development and prospects of the Company and believes that the current share price of the Company does not adequately reflect its intrinsic value and the value as perceived by investors. The Board believes that, depending on the prevailing market conditions and financing arrangements, the Share Repurchase Program is consistent with the Company’s long-term development strategy. The implementation of the Share Repurchase Program will optimise the management of the Company’s capital structure, which is in the interests of the Company and its Shareholders as a whole.

The Company maintains a solid financial position, and intends to finance the repurchase of Shares by its existing available cash while maintaining sufficient financial resources for the continued growth of its operations.

The Share Repurchase Program will be conducted pursuant to the Repurchase Mandate and in compliance with the memorandum of association and the articles of association of the Company, the Listing Rules, The Codes on Takeovers and Mergers and Share Buy-backs (the “**Takeovers Code**”) and all other applicable laws and regulations. The Company will subsequently cancel or hold in treasury the repurchased Shares under the Share Repurchase Program as deemed appropriate by the Board.

The Directors have no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the prescribed minimum percentage as required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code. Shareholders and potential investors should note that any repurchase of Shares made by the Company under the Share Repurchase Program will be subject to market conditions and will be at absolute discretion of the management of the Company. There is no assurance of the timing, quantity or price of any Share repurchase or whether or not the Company will make any Share repurchase.

Shareholders and potential investors are advised to exercise cautions when dealing in the Shares of the Company.

By Order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 27 May 2026

As at the date of this announcement, the Board comprises Mr. An Meng and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua and Professor Zhu Quan as non-executive Directors; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.